Partnership for Parkinson's disease research: Patient-researcher-clinician-sponsor

被引:3
|
作者
Olden, K [1 ]
Guthrie, J [1 ]
Lawler, C [1 ]
机构
[1] NIEHS, Res Triangle Pk, NC 27709 USA
关键词
Parkinson's disease; environment; consortium; oxidative stress;
D O I
10.1016/S0161-813X(02)00030-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease (PD) appears to arise from the interaction of three events-an individual's inherited genetic susceptibility, their subsequent environmental exposures, and their age. We clearly need to intensify efforts to understand the environmental triggers of PD, the importance of the timing of exposure to these triggers, and the interplay between these exposures and a persons underlying genetic constitution and susceptibilities. This knowledge, once generated, will lead to better detection of the earliest stages of PD, to improved therapeutics, and most importantly, to viable prevention strategies so that people need not suffer from environmentally-caused PD. Many promising lines of investigation are already supported by the National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Aging (NIA) and other public and private organizations. In order to accelerate the pace of progress in this field, the NIEHS is developing a Consortium Centers Program that will provide a formal mechanism for "cross-talk" between PD clinicians, basic research scientists, and patient advocates. The Consortium will seek to identify and support novel approaches and research ventures that might not otherwise be pursued by scientists working in isolation. The NIEHS will also continue to explore ways to promote more mechanism-based research to understand putative environmental triggers for PD in concert with defined genetic susceptibilities. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:451 / 456
页数:6
相关论文
共 50 条
  • [31] Pseudopheochromocytoma in a patient with Parkinson's disease
    Duarte, J
    Sempere, AP
    Cabezas, C
    Calvo, T
    Claveria, LE
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (05) : 546 - 546
  • [32] The patient with advanced Parkinson's disease
    Reichmann, H.
    JOURNAL OF NEUROLOGY, 2013, 260 : S6 - S7
  • [33] A Patient-Clinician James Lind Alliance Partnership to identify research priorities for Hyperemesis Gravidarum
    Dean, C.
    Nelson-Piercy, C.
    MacGibbon, K.
    Watford, E.
    Thuis, N. G.
    O'Hara, M.
    Munro, D.
    Cleary, B.
    Shorter, K.
    Trovik, J.
    McBride, M.
    Gadsby, R.
    Clarke, R.
    Penny, H.
    Lodge, K.
    Spijker, R.
    Bierma, H.
    Painter, R.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 : 52 - 52
  • [34] Distinct Clinical Implications of Patient- Versus Clinician-Rated Motor Symptoms in Parkinson's Disease
    Kikuya, Akihiro
    Tsukita, Kazuto
    Sawamura, Masanori
    Yoshimura, Kenji
    Takahashi, Ryosuke
    MOVEMENT DISORDERS, 2024, 39 (10) : 1799 - 1808
  • [35] Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease
    Kane, Patrick Bodilly
    Benjamin, Daniel M.
    Barker, Roger A.
    Lang, Anthony E.
    Sherer, Todd
    Kimmelman, Jonathan
    MOVEMENT DISORDERS, 2021, 36 (01) : 171 - 177
  • [36] Parkinson's disease management pack: Clinician's manual and participant's manual
    Gray, R
    CLINICAL LINGUISTICS & PHONETICS, 1998, 12 (04) : 350 - 351
  • [37] Clinician-researcher's perspectives on clinical research during the COVID19 pandemic
    Silverberg, Sarah L.
    Puchalski Ritchie, Lisa M.
    Gobat, Nina
    Nichol, Alistair
    Murthy, Srinivas
    PLOS ONE, 2020, 15 (12):
  • [38] Improving clinical trials through patient input: Outcomes of a partnership between Pfizer And The Parkinson's Disease Foundation
    Schroeder, K.
    Fenney, M.
    Gray, D.
    Rolph, T.
    Sohur, S.
    Todaro, V.
    MOVEMENT DISORDERS, 2017, 32
  • [39] Priorities in Parkinson's disease research
    Meissner, Wassilios G.
    Frasier, Mark
    Gasser, Thomas
    Goetz, Christopher G.
    Lozano, Andres
    Piccini, Paola
    Obeso, Jose A.
    Rascol, Olivier
    Schapira, Anthony
    Voon, Valerie
    Weiner, David M.
    Tison, Francois
    Bezard, Erwan
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) : 377 - 393
  • [40] Priorities in Parkinson's disease research
    Wassilios G. Meissner
    Mark Frasier
    Thomas Gasser
    Christopher G. Goetz
    Andres Lozano
    Paola Piccini
    José A. Obeso
    Olivier Rascol
    Anthony Schapira
    Valerie Voon
    David M. Weiner
    François Tison
    Erwan Bezard
    Nature Reviews Drug Discovery, 2011, 10 : 377 - 393